BioCentury
ARTICLE | Company News

Fosun gets Chinese rights for Ardelyx's tenapanor

December 12, 2017 11:37 PM UTC

Gastrointestinal company Ardelyx Inc. (NASDAQ:ARDX) granted Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) exclusive rights in China to develop and commercialize tenapanor (AZD1722, RDX5791) to treat irritable bowel syndrome with constipation (IBS-C) and to treat hyperphosphatemia related to chronic kidney disease.

Ardelyx will receive $12 million up front and is eligible for $113 million in milestones, plus tiered royalties in the mid-teens to 20%...